Triorganotin compounds as emerging nuclear retinoid X receptor ligands and their implications in cancer.

Authors

Janette Bobalova, Dana Strouhalova

Published in

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. Jul 16, 2026. Epub Jul 16, 2026.

Abstract

Current efforts in anticancer drug discovery and development are focused on the synthesis and identification of novel complexes that can efficiently and selectively act on DNA and modulate the functions of target proteins. Triorganotins (R₃SnX), as one group of tin complexes, are among the most studied metal-based complexes in the field of anticancer drug development. These compounds have been reported to exhibit promising anticancer activity and provide several potential advantages, including a larger overall surface area, which contributes to increased lipophilicity and consequently higher cytotoxic effects in cancer cells. However, there is still a lack of information on the direct therapeutic targets of triorganotins, their in-depth understanding and useful therapeutic strategies. This review summarizes and critically evaluates current findings regarding triorganotin compounds in oncology research, emphasizing their potential interaction with RXR signaling pathways and the challenges associated with translating these findings into therapeutic practice.

PMID:
42458135
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.